Effects of Hypoglycemic Agents on Vascular Complications in Patients With Adult-Onset Diabetes: VII. Mortality and Selected Nonfatal Events With Insulin Treatment
Abstract
The University Group Diabetes Program is a long-term prospective clinical trial designed to evaluate the effects of various hypoglycemic agents on vascular complications in patients with asymptomatic adult-onset diabetes. Mortality and blood glucose levels were determined as well as certain nonfatal events for patients assigned to diet alone or to either of two insulin treatment regimens. Lower levels of blood glucose with mean values close to normoglycemia were achieved in the treatment group in which the insulin dosage was adjusted to achieve normoglycemia compared with the levels achieved in patients treated with diet alone or with a fixed dose of insulin. In spite of differences in blood glucose levels among the treatment groups, there were only minor differences in the occurrence of fatal or nonfatal events. (JAMA240:37-42, 1978)
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Lowering of glucose by drug treatment generally has not produced anticipated reductions in CHD events.
“although diabetes mellitus and elevated glucose levels clearly predict CHD risk, lowering of glucose by drug treatment generally has not produced anticipated reductions in CHD events, 11,12,12a”
From Beyond Established and Novel Risk Factors: Lifestyle Risk Factors for Cardiovascular Disease (2008) · cites this paper as [11]
Cited by
Sorted by citations
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923 · see citing works
“The current therapeutic approaches have not appreciably altered the high incidence of diabetic complications (3,4).”
BackgroundInfluentialGæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981 · see citing works
Yeaton, W. H., & SECHREST, L. B. (1981) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.49.2.156 · Cited by 501 · see citing works
Congestive Heart Failure in Type 2 Diabetes
Nichols, G. A., Hillier, T. A., Erbey, J. R., & Brown, J. B. (2001) · Diabetes Care · doi:10.2337/diacare.24.9.1614 · Cited by 600 · see citing works
(1995) · BMJ · doi:10.1136/bmj.310.6972.83 · Cited by 478 · see citing works
Grover, J. K., Vats, V., & Rathi, S. S. (2000) · Journal of Ethnopharmacology · doi:10.1016/s0378-8741(00)00319-6 · Cited by 415 · see citing works
Turner, R., Cull, C., Holman, R. R., & United Kingdom Prospective Diabetes Study Group (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-1_part_2-199601011-00011 · Cited by 464 · see citing works
“It also compares the UKPDS with two previously reported studies—the DCCT (21) and UGDP (7)—both of which reported data for 9 years of follow-up.”
BackgroundMethodResultInfluentialAge-related changes in glucose metabolism, hyperglycemia, and cardiovascular risk
Chia, C. W., Egan, J. M., & Ferrucci, L. (2018) · Circulation Research · doi:10.1161/circresaha.118.312806 · Cited by 454 · see citing works
“The study was continued in the 2 insulin groups because their macrovascular or microvascular complications and mortality were no different from placebo; however, results remained the same after 13 years of follow-up with no obvious benefit to insulin treatment in either insulin groups.(186,187) In the 2000s, thiazoled…”
Beyond Established and Novel Risk Factors: Lifestyle Risk Factors for Cardiovascular Disease
Mozaffarian, D., Wilson, P. W. F., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.738732 · Cited by 456 · see citing works
Hemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T., Hemmingsen, C., & Wetterslev, J. (2011) · BMJ · doi:10.1136/bmj.d6898 · Cited by 386 · see citing works
The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is … or is it?
Nathan, D. M., Meigs, J. B., & Singer, D. E. (1997) · The Lancet · doi:10.1016/s0140-6736(97)90021-0 · Cited by 264 · see citing works
UK prospective diabetes study (UKPDS)
UK Prospective Diabetes Study Group (1991) · Diabetologia · doi:10.1007/bf00400195 · Cited by 565 · see citing works
Insulin resistance is a cardiovascular risk factor in humans
Adeva‐Andany, M. M., Martínez‐Rodríguez, J., González-Lucán, M., Fernández‐Fernández, C., & Castro-Quintela, E. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.02.023 · Cited by 314 · see citing works
Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention
Laakso, M. (2001) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2001.00789.x · Cited by 251
Harris, R., Donahue, K. E., Rathore, S. S., Frame, P., Woolf, S. H., & Lohr, K. N. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-3-200302040-00015 · Cited by 110 · see citing works
“Only two of these trials included persons with diabetes who had received recent diagnoses (10, 49); in neither study was diabetes detected primarily by screening.”
BackgroundScreening for Diabetic Retinopathy
Singer, D. E., Nathan, D. M., Fogel, H. A., & SCHACHAT, A. P. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-8-660 · Cited by 296 · see citing works
“The only controlled clinical trial to examine the effects of improved glucose control in patients with type II diabetes was the University Group Diabetes Program (UGDP) trial, which demonstrated no differences in the occurrence of retinopathy among treatment groups (51).”
BackgroundCardiac consequences of diabetes mellitus
SHEHADEH, A. A., & Regan, T. J. (1995) · Clinical Cardiology · doi:10.1002/clc.4960180604 · Cited by 164 · see citing works
Insulin resistance and coronary heart disease
Laakso, M. (1996) · Current Opinion in Lipidology · doi:10.1097/00041433-199608000-00008 · Cited by 151 · see citing works
Melton, L. J., Kathleen, M. M., Palumbo, P. J., & Elveback, L. R. (1980) · Diabetes Care · doi:10.2337/diacare.3.6.650 · Cited by 143 · see citing works
DIABETES MELLITUS AND CORONARY HEART DISEASE
Wilson, P. W. F. (2001) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70219-x · Cited by 79 · see citing works
The DECODE Insulin Study Group (2004) · Diabetologia · doi:10.1007/s00125-004-1433-4 · Cited by 159 · see citing works
Muniappan, L., & Pari, L. (2003) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.2003.03785.x · Cited by 97 · see citing works
Declining mortality in coronary heart disease.
Levy, R. I. (1981) · Arteriosclerosis · doi:10.1161/01.atv.1.5.312 · Cited by 120 · see citing works
Relationship between serum sex hormones and the glucose-insulin-lipid defect in men with obesity
Phillips, G. B. (1993) · Metabolism · doi:10.1016/0026-0495(93)90181-m · Cited by 116 · see citing works
Hasan, R., Firwana, B., Elraiyah, T. A., Domecq, J. P., Prutsky, G. J., Nabhan, M., Prokop, L. J., Henke, P. K., Τσάπας, Α., Montori, V. M., et al. (2016) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2015.10.005 · Cited by 131 · see citing works
Tests of Glycemia in Diabetes Mellitus
Singer, D. E., Coley, C. M., Samet, J. H., & Nathan, D. M. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-2-125 · Cited by 77 · see citing works
The incidence of congestive heart failure associated with antidiabetic therapies
Nichols, G. A., Koro, C. E., Gullion, C. M., Ephross, S. A., & Brown, J. B. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.480 · Cited by 105 · see citing works
Savage, P. J. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-1_part_2-199601011-00008 · Cited by 104 · see citing works
A Rational Approach to Drug Therapy of Type 2 Diabetes Mellitus
Chehade, J. M., & Mooradian, A. D. (2000) · Drugs · doi:10.2165/00003495-200060010-00006 · Cited by 138 · see citing works
“Prospective studies evaluating the effect of insulin on cardiovascular morbidity and/ormortality in patients with type 2 diabetes have so far yielded somewhat conflicting results.[42-48] Overall, evidence currently available from the recently completed United Kingdom Prospective Diabetes Study (UKPDS) indicates that e…”
BackgroundWhat cardiologists need to know about diabetes
Webster, M. W. I., & Scott, R. S. (1997) · The Lancet · doi:10.1016/s0140-6736(97)90025-8 · Cited by 87 · see citing works
Genuth, S. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-1_part_2-199601011-00005 · Cited by 92 · see citing works
Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes
Lebovitz, H. E. (2011) · Diabetes Care · doi:10.2337/dc11-s225 · Cited by 97 · see citing works
“The University Group Diabetes Program (UGDP) was a randomized controlled trial of patients with early adultonset diabetes treated with placebo (diet), tolbutamide, or insulin (12,13).”
MethodStandards of Care for Diabetes
Weir, G., Nathan, D., & Singer, D. E. (1994) · Diabetes Care · doi:10.2337/diacare.17.12.1514 · Cited by 83 · see citing works
“The only completed trial of glycemic control in NIDDM, the University Group Diabetes Project (UGDP) study, did not observe a benefit of insulin therapy in preventing vascular complications, and did observe an unexpected increase in cardiovascular mortality with tolbutamide (22,23).”
BackgroundDoes Hyperglycemia Really Cause Coronary Heart Disease?
Barrett-Connor, E. (1997) · Diabetes Care · doi:10.2337/diacare.20.10.1620 · Cited by 82 · see citing works
“This need was recognized in the 1950s and has resulted in the University Group Diabetes Program (UGDP; [21]), which began in 1961 and was completed in 1975 (22).”
BackgroundEPIDEMIOLOGY OF LATE DIABETIC COMPLICATIONS
Królewski, A. S., Warram, J. H., & Freire, M. B. S. (1996) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70322-4 · Cited by 121 · see citing works
Diabetic retinopathy. A clinical overview.
Davis, M. D. (1988) · Diabetes Care · doi:10.1002/dmr.5610040402 · Cited by 82 · see citing works
Liu, Q. Z., Knowler, W., Nelson, R., et al. (1992) · Diabetes · doi:10.2337/diab.41.9.1141 · Cited by 81 · see citing works
Hemmingsen, B., Lund, S. S., Gluud, C. N., Vaag, A. A., Almdal, T., & Wetterslev, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub4 · Cited by 287 · see citing works
RetractedThe Course of Peripheral Vascular Disease in Non-insulin-dependent Diabetes
Kreines, K., Johnson, E., Albrink, M., et al. (1985) · Diabetes Care · doi:10.2337/diacare.8.3.235 · Cited by 77
Self-citationProliferative Diabetic Retinopathy
Shah, K. B., & Han, D. P. (2004) · International Ophthalmology Clinics · doi:10.1097/00004397-200404440-00007 · Cited by 94 · see citing works
Fuessl, H., Williams, G., Adrian, T. E., et al. (1987) · Diabetic Medicine · doi:10.1111/j.1464-5491.1987.tb00910.x · Cited by 70 · see citing works
Hu, S.-L., Wang, S.-Y., & Dunning, B. E. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35248-6 · Cited by 66 · see citing works
HYPERGLYCEMIA AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE IN TYPE 2 DIABETES
Laakso, M. (1999) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(05)70133-0 · Cited by 57 · see citing works
Therapy of type 2 diabetes, cardiovascular death, and the UGDP.
Feinglos, M., & Bethel, M. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70034-7 · Cited by 59 · see citing works
Fang, H.-J., Zhou, Y.-H., Tian, Y.-J., Du, H.-Y., Sun, Y.-X., & Zhong, L.-Y. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.163 · Cited by 57 · see citing works
Diabetes as a stigmatized condition: The case of low-income clinic patients in the United States
Hopper, S. V. (1981) · Social Science & Medicine Part B Medical Anthropology · doi:10.1016/0160-7987(81)90004-1 · Cited by 43 · see citing works
Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM
Schmitz, A., V�th, M., & Mogensen, C. E. (1994) · Diabetologia · doi:10.1007/bf00399799 · Cited by 95 · see citing works
“Glycaemic control has been shown to be important with regard to the development of diabetic microvascular complications [33-38], whereas its influence on macrovascular disabilities so far is doubtful [ 39-42 ].”
BackgroundThe Achilles heel of the University Group Diabetes Program.
Kilo, C., Miller, J. D., & Williamson, J. R. (1980) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.1980.03300310038020 · Cited by 56 · see citing works
Are Conventional Risk Factors for Mortality Relevant in Type 2 Diabetes?
Fitzgerald, A. J., & Jarrett, R. J. (1991) · Diabetic Medicine · doi:10.1111/j.1464-5491.1991.tb01635.x · Cited by 48 · see citing works
Cardiovascular Disease Prevention Practices by U.S. Physicians for Patients with Diabetes
Meigs, J. B., & Stafford, R. S. (2000) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2000.03079.x · Cited by 63 · see citing works
VASCULAR DISEASE AND LIPIDS IN DIABETES
Garber, A. J. (1998) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70030-4 · Cited by 46 · see citing works
Implications of the United Kingdom prospective diabetes study.
Baldeweg, S., & Yudkin, J. (1999) · Primary Care · doi:10.1016/s0095-4543(05)70132-9 · Cited by 49
Treatment of NIDDM With Insulin Agonists or Substitutes
Galloway, J. (1990) · Diabetes Care · doi:10.2337/diacare.13.12.1209 · Cited by 48
“Davis also cited results of the UGDP (138) that raise questions about the relationship of glycemic control and the progression of retinopathy in NIDDM.”
BackgroundThe ACCORD Trial and Control of Blood Glucose Level in Type 2 Diabetes Mellitus
Havas, S. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.518 · Cited by 41 · see citing works
Noor, H., Hammonds, P., Sutton, R., et al. (1989) · Diabetologia · doi:10.1007/bf00277258 · Cited by 45
Approach to diabetes management in patients with CVD
Lathief, S., & Inzucchi, S. E. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.05.005 · Cited by 55 · see citing works
“As noted, the UGDP study showed evidence of CV mortality with tolbutamide leading to a FDA black box warning and discontinuation of this drug from the market [54].”
BackgroundInfluentialDyslipidaemia and cardiovascular risk in diabetes
Cullen, P., von Eckardstein, A., Souris, S., Schulte, H., & Assmann, G. (1999) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.1999.00030.x · Cited by 39 · see citing works
UK prospective study of therapies of maturity-onset diabetes
Turner, R. C., Mann, J. I., & Peto, R. (1984) · Diabetologia · doi:10.1007/bf00304862 · Cited by 38 · see citing works
Ethanol extract of Gymnema montanum leaves reduces glycoprotein components in experimental diabetes
Ramkumar, K. M., Rajaguru, P., Muniappan, L., & Rajendran, A. (2007) · Nutrition Research · doi:10.1016/j.nutres.2006.12.010 · Cited by 33 · see citing works
Wertz, D., Chang, C., Sarawate, C. A., et al. (2010) · Circulation. Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.109.911461 · Cited by 39
Preventing macrovascular complications in type 2 diabetes mellitus: glucose control and beyond.
Stancoven, A. B., & Mcguire, D. K. (2007) · American Journal of Cardiology · doi:10.1016/j.amjcard.2007.04.005 · Cited by 37 · see citing works
Spin-off cost/benefits of expanded nutritional care.
Davidson, J. K., Delcher, H. R., & Englund, A. (1979) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(21)05337-2 · Cited by 37
Dale, A. C., Midthjell, K., Nilsen, T. I. L., Wiseth, R., & Vatten, L. J. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp039 · Cited by 34 · see citing works
Corrao, G., Romio, S., Zambon, A., Merlino, L. G., Bosi, E., & Scavini, M. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0939-6 · Cited by 31 · see citing works
“However, concerns about the potential adverse cardiovascular effects of oral hypoglycaemic agents that increase insulin exposure, specifically sulphonylurea medications, have been raised since 1970 by the University Group Diabetes Project (UGDP) [10, 11].”
BackgroundInfluentialPharmacotherapy of Type 2 Diabetes Mellitus
Rendell, M., & Kirchain, W. R. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19171 · Cited by 30 · see citing works
The natural history of diabetes‐related complications: the UKPDS experience
Matthews, D. R. (1999) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.1999.0010s2007.x · Cited by 32 · see citing works
The UK Prospective Diabetes Study.
Bailey, C., & Grant, P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)00090-7 · Cited by 33 · see citing works
Insulin resistance and atherosclerosis. Common roots for two common diseases?
Taegtmeyer, H. (1996) · Circulation · doi:10.1161/01.cir.93.10.1777 · Cited by 33
Screening for Diabetes Mellitus
Singer, D. E., Samet, J. H., Coley, C. M., & Nathan, D. M. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-8-639 · Cited by 48 · see citing works
Ahmad, N., Bansal, R., Rastogi, A., et al. (1984) · Acta Diabetologica Latina · doi:10.1007/bf02624765 · Cited by 32
Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD
Hoogwerf, B. J. (2008) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.75.10.729 · Cited by 24 · see citing works
Glycemic control and cardiovascular disease in Type 2 diabetes: a review
Wild, S. H., Dunn, C. J., McKeigue, P., & Comte, S. (1999) · Diabetes/Metabolism Research and Reviews · doi:10.1002/(sici)1520-7560(199905/06)15:3 · Cited by 26 · see citing works
EPIDEMIOLOGY OF NON-INSULIN-DEPENDENT DIABETES MELLITUS AND ITS MACROVASCULAR COMPLICATIONS
Warram, J. H., Kopczyński, J., Janka, H. U., & Królewski, A. S. (1997) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70239-5 · Cited by 25 · see citing works
Glucose control in diabetes: which target level to aim for?
Laakso, M., & Cederberg, H. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02528.x · Cited by 24 · see citing works
Rajendran, A., Muniappan, L., Pari, L., Ramkumar, K. M., Baskar, C. G., & Bai, V. N. (2003) · Journal of Medicinal Food · doi:10.1089/109662003765184732 · Cited by 20 · see citing works
Diabetic microangiopathy, genetics, environment, and treatment.
Siperstein, M. D. (1988) · American Journal of Medicine · doi:10.1016/0002-9343(88)90404-4 · Cited by 28 · see citing works
Waeber, B., Feihl, F., & Ruilope, L. M. (2001) · Blood Pressure · doi:10.1080/080370501753400610 · Cited by 43 · see citing works
Efficacy and safety of oral hypoglycemic agents.
Selizer, H. S. (1980) · doi:10.1146/annurev.me.31.020180.001401 · Cited by 27
UK prospective study of therapies of maturity-onset diabetes
Turner, R. C., Mann, J. I., Iceton, G., Oakes, S., Smith, A., Moore, J., Hockaday, T. D. R., Holman, R. R., Stowers, J., Stowers, M., et al. (1983) · Diabetologia · doi:10.1007/bf00257337 · Cited by 87 · see citing works
“The reduction of median fasting plasma glucose in this study by insulin or sulphonylurea was nearly twice that achieved by the UGDP study at the same stage [8, 10].”
ResultPrevention of Microvascular Complications of Diabetes
Bloomgarden, Z. T., & Gouller, A. (2004) · Springer eBooks · doi:10.1007/978-1-4757-6260-0_33 · Cited by 1 · see citing works
Li, J., Dong, Y., Wu, T., & Tong, N. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12361 · Cited by 25 · see citing works
“Of the three trials that met the inclusion criteria, one study was excluded because it compared all-cause mortality and cardiovascular deaths in White and non-White patients; moreover, some of the patients with T2D had impaired glucose tolerance according to current diagnostic criteria.(12,13) Because the non-White gr…”
ResultValue of glucose control in preventing complications of diabetes.
Kilo, C. (1985) · American Journal of Medicine · doi:10.1016/0002-9343(85)90583-2 · Cited by 25 · see citing works
Takeda, S., Ueshiba, H., Hattori, Y., & Irie, M. (1999) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00053-4 · Cited by 24 · see citing works
Cathelineau, G., Champvallins, M. D., Bouallouche, A., & Lesobre, B. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90314-0 · Cited by 17 · see citing works
Cardiovascular Safety of Oral Antidiabetic Agents: The Insulin Secretagogues
Caulfield, M., & O'Brien, K. (2002) · Clinical Diabetes · doi:10.2337/diaclin.20.2.81 · Cited by 20 · see citing works
Jarrett, R. (1988) · Diabetologia · doi:10.1007/bf00395550 · Cited by 20 · see citing works
“Mortality and morbidity were reported for 13 years of follow-up in the 2 insulin-treated groups (insulin standard and insulin variable) compared with the placebo treated group [26].”
BackgroundMultifactorial aspects of the treatment of the type II diabetic patient.
Colwell, J. A. (1997) · Metabolism: Clinical and Experimental · doi:10.1016/s0026-0495(97)90308-5 · Cited by 19
Approach to the management of diabetic patients with heart failure: Role of thiazolidinediones
Fonarow, G. C. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.04.033 · Cited by 22 · see citing works
Lu, W., Resnick, H. E., Jablonski, K. A., Jain, A. K., Jones, K. L., Robbins, D. C., & Howard, B. V. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01137.x · Cited by 15 · see citing works
Sunday, J., & Eyles, J. D. (2001) · Social Science & Medicine (1967) · doi:10.1016/s0277-9536(00)00166-0 · Cited by 17 · see citing works
Haaber, A., Kofoed-Enevoldsen, A., & Jensen, T. (1992) · Diabetic Medicine · doi:10.1111/j.1464-5491.1992.tb01838.x · Cited by 17
Pathogenesis and Pathology of Coronary Heart Disease Syndromes
Ridker, P. M., & Antman, E. M. (1999) · Journal of Thrombosis and Thrombolysis · doi:10.1023/a:1008997801820 · Cited by 17 · see citing works
“When the University Group Diabetes Program evaluated the effects of several oral hypoglycemic agents and two insulin regimens versus placebo in patients with adult-onset diabetes, they found that the drugs offered no bene~t in controlling the vascular complications of diabetes [68, 69 ] Since there is some evidence th…”
BackgroundKilo, C., Miller, J. D., & Williamson, J. R. (1980) · Diabetologia · doi:10.1007/bf00251913 · Cited by 16 · see citing works
Hoogwerf, B. J. (1991) · Springer eBooks · doi:10.1007/978-1-4612-3014-4_8 · Cited by 9 · see citing works
Glucose Control and Cardiovascular Disease
Conget, I., & Giménez, M. (2009) · Diabetes Care · doi:10.2337/dc09-s334 · Cited by 19 · see citing works
“Project (409 participants) may be considered the first glucose-lowering trial evaluating the CV effects of different strategies aimed at glucose control in type 2 diabetes (insulin addressed/not addressed to intensive control, phenformin, tolbutamide, and placebo) (14,15).”
BackgroundDurrington, P. N. (1992) · Diabetic Medicine · doi:10.1111/j.1464-5491.1992.tb01852.x · Cited by 17 · see citing works
The relationship between metabolic control and vascular complications of diabetes mellitus.
Godine, J. E. (1988) · The Medical clinics of North America · doi:10.1016/s0025-7125(16)30706-4 · Cited by 12 · see citing works
The University Group Diabetes Program 1961-1978: pioneering randomized controlled trial
BLACKBURN, H. W., & Jacobs, D. R. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw168 · Cited by 15 · see citing works
ESTIMATING THE MICROVASCULAR BENEFITS OF SCREENING FOR TYPE 2 DIABETES MELLITUS
Hofer, T., Vijan, S., & Hayward, R. A. (2000) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462300102090 · Cited by 11 · see citing works
“While a 10% one-time reduction in HbA1c fits the data published from the randomized trials, we also estimated a model in which we used the absolute mean effect from the trials (about one percentage point drop in HbA1c), regardless of the starting level (5;12;18).”
BackgroundMethodInfluential
- Authors
- Knatterud, G. L.
- Corresponding author
- Knatterud, Genell L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1978-07-07
- Volume
- 240
- Issue
- 1
- Pages
- 37
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W7214171970
- Cited by
- 0
- References
- 0
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, antidiabetic drugs, insulin therapy, dietary therapy, glycemic control, normoglycemia, vascular complications, mortality, University Group Diabetes Program
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
